Response to hydroxychloroquine in Japanese patients with systemic lupus erythematosus using the cutaneous lupus erythematosus disease area and severity index (CLASI)

Modern Rheumatology

Volumn 22, Issue 2, 2012, Pages 249-255

  Yokogawa, Naoto ^a   Kato, Yukihiko ^a   Sugii, Shoji ^a   Inada, Shinichi ^a  

^a TOKYO METROPOLITAN TAMA MEDICAL CENTER   (Japan)

Author keywords

Cutaneous lupus erythematosus; Cutaneous lupus erythematosus disease area and severity index (CLASI); Hydroxychloroquine; Systemic lupus erythematosus

Indexed keywords

AZATHIOPRINE; HYDROXYCHLOROQUINE; MIZORIBINE; PREDNISOLONE; TACROLIMUS;

ADULT; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; CUTANEOUS LUPUS ERYTHEMATOSUS DISEASE AREA AND SEVERITY INDEX; CUTANEOUS PARAMETERS; DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS; DISCOID LUPUS ERYTHEMATOSUS; DISEASE ACTIVITY; DISEASE SEVERITY; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; JAPANESE; MALAISE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SKIN LUPUS ERYTHEMATOSUS; SYSTEMIC LUPUS ERYTHEMATOSUS; THERAPY EFFECT; TREATMENT RESPONSE; VISUAL ANALOG SCALE;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRALGIA; FEMALE; HUMANS; HYDROXYCHLOROQUINE; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; PAIN MEASUREMENT; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; SKIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84861479592     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-011-0503-y     Document Type: Article

References (26)

1. Kuhn A, Ruland V, Bonsmann G. Cutaneous lupus erythematosus: update of therapeutic options Part I. J Am Acad Dermatol. 2010. Epub ahead of print.
2. The Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulphate in systemic lupus erythematosus. N Engl J Med. 1991;324:150-4.
3. Fessler BJ, Alarcón GS, McGwin G Jr, Roseman J, Bastian HM, Friedman AW, et al. Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum. 2005;52: 1473-80. (Pubitemid 40663939)
4. Alarcón GS, McGwin G, Bertoli AM, Fessler BJ, Calvo-Alén J, Bastian HM, et al. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis. 2007;66:1168-72. (Pubitemid 47309732)
5. Ruiz-Irastorza G, Egurbide MV, Pijoan JI, Garmendia M, Villar I, Martinez-Berriotxoa A, et al. Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus. 2006;15:577-83. (Pubitemid 44661744)
6. Ruiz-Irastorza G, Olivares N, Ruiz-Arruza I, Martinez-Berriotxoa A, Egurbide MV, Aguirre C. Predictors of major infections in systemic lupus erythematosus. Arthritis Res Ther. 2009;11(4):R109.
7. Shinjo SK, Bonfá E, Wojdyla D, Borba EF, Ramirez LA, Scherbarth HR, et al. Antimalarial treatment may have a time-dependent effect on lupus survival: data from a multinational Latin American inception cohort. Arthritis Rheum. 2010;62:855-62.
8. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus. Ann Rheum Dis. 2010;69:20-8.
9. Albrecht J, Taylor L, Berlin JA, Dulay S, Ang G, Fakharzadeh S, et al. The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus. J Invest Dermatol. 2005;125:889-94.
10. Klein R, Moghadam-Kia S, LoMonico J, Okawa J, Coley C, Taylor L, et al. Development of the CLASI as a tool to measure disease severity and responsiveness to therapy in cutaneous lupus erythematosus. Arch Dermatol. 2011;147:203-8.
11. Jewell ML, McCauliffe DP. Patients with cutaneous lupus erythematosus who smoke are less responsive to antimalarial treatment. J Am Acad Dermatol. 2000;42:983-7. (Pubitemid 30368665)
12. Isenberg DA, Rahman A, Allen E, Farewell V, Akil M, Bruce IN, et al. BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus. Rheumatology. 2005;44:902-6. (Pubitemid 41511186)
13. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25:1271-7. (Pubitemid 13221242)
14. Albrecht J, Werth VP. Clinical outcome measures for cutaneous lupus erythematosus. Lupus. 2010;19:1137-43.
15. Chang AY, Piette EW, Foering KP, Tenhave TR, Okawa J, Werth VP. Response to antimalarials in cutaneous lupus erythematosus: a prospective analysis. Arch Dermatol. 2011 [Epub ahead of print].
16. Kreuter A, Gaifullina R, Tigges C, Kirschke J, Altmeyer P, Gambichler T. Lupus erythematosus tumidus response to anti-malarial treatment in 36 patients with emphasis on smoking. Arch Dermatol. 2009;145:244-8.
17. Tsuchida T. Classification of lupus erythematosus based upon Japanese patients. Autoimmun Rev. 2009;8:453-5.
18. Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria for Fatigue. Measurement of fatigue in systemic lupus erythematosus: a systematic review. Arthritis Rheum.2007;57:1348-57.
19. Askanase AD, Castrejón I, Pincus T. Quantitative data for care of patients with systemic lupus erythematosus in usual clinical settings: a patient multidimensional health assessment questionnaire and physician estimate of noninflammatory symptoms. J Rheumatol. 2011;38:1309-16.
20. The HERA Study Group. A randomized trial of hydroxychloroquine in early rheumatoid arthritis: the HERA Study. Am J Med. 1995;98:156-68.
21. Wolfe F, Marmor MF. Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res. 2010;62:775-84.
22. Michaelides M, Stover NB, Francis PJ, Weleber RG. Retinal toxicity associated with hydroxychloroquine and chloroquine: risk factors, screening, and progression despite cessation of therapy. Arch Ophthalmol. 2011;129:30-9.
23. Ogawa S, Kurumatani N, Shibaike N, Yamazoe S. Progression of retinopathy long after cessation of chloroquine therapy. Lancet. 1979;1:1408. (Pubitemid 9204172)
24. Yokogawa N. Hydroxychloroquine and mycophenolate mofetil. Curr Ther. 2010;28:85-91. (in Japanese).
25. Ochsendorf FR. Use of antimalarials in dermatology. J Dtsch Dermatol Ges. 2010;10:829-44.
26. Kalia S, Dutz JP. New concepts in antimalarial use and mode of action in dermatology. Dermatol Ther. 2007;20:160-74. (Pubitemid 350029307)